Evidence map›Paper›PMID 32929442›Full record

ReviewNatural product reports2021

Leveraging orthogonal mass spectrometry based strategies for comprehensive sequencing and characterization of ribosomal antimicrobial peptide natural products.

Tessa B Moyer, Nicole C Parsley, Patric W Sadecki, Wyatt J Schug, Leslie M Hicks

Open access · greenAbstract readReview
In one paragraph

Review in Natural product reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tessa B MoyerDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. lmhicks@unc.edu.
Nicole C Parsley
Patric W Sadecki
Wyatt J Schug
Leslie M Hicks
University of North Carolina at Chapel Hill · US

Funding

MOLECULAR AND CELLULAR BIOPHYSICS TRAINING PROGRAMT32GM008570 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KUHLMAN, BRIAN A, SLEP, KEVIN C · 1995 to 2022
$5.1M
PepSAVI-MS for discovery of novel botanical antimicrobial peptidesR01GM125814 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HICKS, LESLIE M. · 2018 to 2022
$1.6M
NIGMS NIH HHS R01 GM125814NIGMS NIH HHS T32 GM008570
6 · The paper itself

Abstract

Covering: Up to July 2020Ribosomal antimicrobial peptide (AMP) natural products, also known as ribosomally synthesized and post-translationally modified peptides (RiPPs) or host defense peptides, demonstrate potent bioactivities and impressive complexity that complicate molecular and biological characterization. Tandem mass spectrometry (MS) has rapidly accelerated bioactive peptide sequencing efforts, yet standard workflows insufficiently address intrinsic AMP diversity. Herein, orthogonal approaches to accelerate comprehensive and accurate molecular characterization without the need for prior isolation are reviewed. Chemical derivatization, proteolysis (enzymatic and chemical cleavage), multistage MS fragmentation, and separation (liquid chromatography and ion mobility) strategies can provide complementary amino acid composition and post-translational modification data to constrain sequence solutions. Examination of two complex case studies, gomesin and styelin D, highlights the practical implementation of the proposed approaches. Finally, we emphasize the importance of heterogeneous AMP peptidoforms that confer varying biological function, an area that warrants significant further development.

Indexed as

AlkylationAmino AcidsAntimicrobial Cationic PeptidesBiological ProductsCyclizationGlycosylationMass SpectrometryPore Forming Cytotoxic ProteinsProtein Processing, Post-TranslationalStereoisomerismAmino AcidsAntimicrobial Cationic PeptidesBiological ProductsgomesinPore Forming Cytotoxic Proteinsstyelin D

Identifiers

PMID32929442
PMCPMC7956910
OpenAlexW3087144824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.